Francesco De Rubertis makes his legacy play, recruiting star execs and rolling up 10 biotech startups into a $250M gamble on creating something new in pharma
A prominent venture startup shop with deep roots in European R&D circles is making a $250 million wager that it can create a new kind of pharma company — one with some star portfolio players promising to come together to lead the way to unicorn-style success rates.
Saurabh Saha, whose career has wound in and out of big pharma and the startup world, has left his post as global head of translational research for Bristol Myers and taken the top spot as CEO of the new company, called Centessa, for reasons I’ll explain soon.
Premium subscription required
Unlock this article along with other benefits by subscribing to one of our paid plans.